HBsAg(+), anti-HBc(+), but anti-HCV(−);Free of HDV and HIV infection;Free of other liver diseases, including autoimmune or toxic hepatitis and primary biliary cirrhosis;Replication phase: 6 cohorts with pooled results;Significance determined using p < 5 × 10−3 and LD r2 < 0.2 between markers. Here, KRT88P is linked to liver disorder.